Association of catechol-o-methyl transferase gene polymorphism with prostate cancer and benign prostatic hyperplasia

被引:0
作者
Omrani, Mir Davood [1 ]
Bazargani, Soroush [2 ]
Bagheri, Morteza [1 ]
Yazdan-nejad, Hamed [2 ]
机构
[1] Urmia Univ Med Sci, Dept Genet, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Dept Urol, Orumiyeh, Iran
来源
JOURNAL OF RESEARCH IN MEDICAL SCIENCES | 2009年 / 14卷 / 04期
关键词
Prostate Cancer; Benign Prostatic Hyperplasia; COMT 158Val/Met Polymorphism; BREAST-CANCER; METHYLTRANSFERASE PHARMACOGENETICS; JAPANESE POPULATION; ENDOMETRIAL CANCER; RISK; WOMEN; DNA;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: A single nucleotide variation within catechol-o-methyl transferase (COMT) gene may alter the COMT enzyme activity level. Polymorphism of Val 158Met in the COMT gene has been related to malignancy. In this regard, a Study was carried out to find a possible association between the COMT gene polymorphism in patients with sporadic prostate cancer (PCa) and benign prostatic hyperplasia (BPH). METHODS: All types of COMT 158 Val/Met polymorphism were carried out using ASO-PCR method in 41 patients with prostate cancer, 193 patients with benign prostatic hyperplasia and 107 healthy male individuals. RESULTS: The results of this study showed that the frequency of low producer allele A at codon 158 of the COMT gene is significantly different in BPH group compared to normal male control group (OR, 95% CI, p value 1.95: 1.46, 2.44, 0.021, respectively). However no significant difference was noticed when the comparison was made between prostate cancer group and normal male control group and also between BPH and PCa groups. CONCLUSIONS: Decreased level of catechol-o-methyl trans prostatic hyperplasia development but not in prostate cancer role against BPH.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 27 条
[1]   HUMAN LIVER CATECHOL-O-METHYLTRANSFERASE PHARMACOGENETICS [J].
BOUDIKOVA, B ;
SZUMLANSKI, C ;
MAIDAK, B ;
WEINSHILBOUM, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (04) :381-389
[2]   Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer [J].
Cavalieri, EL ;
Devanesan, P ;
Bosland, MC ;
Badawi, AF ;
Rogan, EG .
CARCINOGENESIS, 2002, 23 (02) :329-333
[3]   Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer [J].
Doherty, JA ;
Weiss, NS ;
Freeman, RJ ;
Dightman, DA ;
Thornton, PJ ;
Houck, JR ;
Voigt, LF ;
Rossing, MA ;
Schwartz, SM ;
Chen, C .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (02) :357-366
[4]   Prostate cancer epidemiology [J].
Grönberg, H .
LANCET, 2003, 361 (9360) :859-864
[5]  
HABIBI A, 1975, INT SURG, V60, P405
[6]  
Habuchi T, 2000, CANCER RES, V60, P305
[7]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[8]   Neuroleptic binding to sigma receptors: Possible involvement in neuroleptic-induced acute dystonia [J].
Jeanjean, AP ;
Laterre, EC ;
Maloteaux, JM .
BIOLOGICAL PSYCHIATRY, 1997, 41 (10) :1010-1019
[9]   Distribution of catechol-O-methyltransferase expression in human central nervous system [J].
Jiang, H ;
Ho, SL ;
Xie, T ;
Young, LP .
NEUROREPORT, 1998, 9 (12) :2861-2864
[10]   CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity [J].
Kitagawa, K ;
Kunugita, N ;
Kitagawa, M ;
Kawamoto, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (21) :17830-17835